在患有肠道衰竭的儿科患者中,提前使用泰杜格卢类药物与更高的反应率有关:一项多中心研究
Marta Germán-Díaz1, Alida Alcolea2, Vanessa Cabello3
1Pediatric Gastroenterology, Hepatology and Nutrition Department, Hospital Universitario, 12 de Octubre, Madrid, Spain. marta.german@salud.madrid.org.
European journal of pediatrics
|April 25, 2024
概括
泰杜格卢提德有效地减少了患有短肠综合征 (SBS) 的儿童的腹腔营养需求. 在较年轻的年龄开始治疗与更好的结果和潜在的断奶与支持有关.
科学领域:
- 儿科胃肠病学 儿科胃肠病学
- 临床药理学 临床药理学
- 胃肠道适应 胃肠道适应
背景情况:
- 短肠综合征 (SBS) 在儿科患者中带来了重大挑战,通常需要长期的肠外营养 (PN).
- 作为一种类似于葡萄糖类-2 (GLP-2) 的类似物,泰杜格卢提德 (Teduglutide) 在降低PN需求方面表现有前途,但对其在儿童中长期使用的现实数据仍然有限.
研究的目的:
- 在西班牙的五年时间内,评估特杜格胺在肠道衰竭 (IF) 的儿科患者群体中的实际有效性和安全性.
- 评估泰杜格胺对PN要求的影响,并确定影响治疗反应的因素.
主要方法:
- 一项前性多中心研究,涉及31名患有IF的儿科患者,他们接受了至少三个月的泰杜格卢类药物治疗.
- 收集的数据包括人口统计,病史,人体测量,实验室值,不良事件和PN要求,通过REDCap数据库进行分析.
主要成果:
- 80%的患者每周PN能量减少了20%以上,77%的PN体积减少了20%以上.
- 9名患者 (29%) 成功戒除了PN,治疗时间中位数为6个月.
- 治疗开始时的年龄较小显著与每周PN体积的较大减少有关 (p=0.028).
结论:
- 泰杜格卢提德 (Teduglutide) 证明了FI的儿科患者的疗效和安全性,包括SBS患者.
- 对于一些患者来说,可能需要长期治疗才能实现肠道自主.
- 在儿童中,提早启动泰杜格卢类药物治疗与治疗反应的可能性更高有关.
相关概念视频
01:17Drugs for Treatment of Diarrhea-Predominant IBS
161
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
161
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
116
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
116
01:15Enteral Nutrition II: Nasointestinal and Gastrostomy Feeding
119
Enteral nutrition encompasses various methods of delivering nutrition directly to the gastrointestinal (GI) tract, bypassing traditional oral intake. It is particularly beneficial for patients who cannot eat by mouth but have a functioning digestive system. Key methods include nasointestinal feeding, gastrostomy, and jejunostomy, each suited to different clinical scenarios based on the patient's needs and condition.
Nasointestinal Feeding
Nasointestinal feeding involves placing a tube...
Nasointestinal Feeding
Nasointestinal feeding involves placing a tube...
119
01:21Factors Affecting Drug Response: Overview
2.0K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
2.0K
01:21Drugs for Treatment of Constipation-Predominant IBS
160
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
160
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
249
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
249